Monopar Therapeutics Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2022 | — | $17.0M | $17.8M |
| Jun 2022 | — | $14.5M | $16.5M |
| Sep 2022 | — | $12.5M | $14.3M |
| Dec 2022 | — | $10.1M | $8.2M |
| Mar 2023 | — | $8.9M | $5.7M |
| Jun 2023 | — | $7.8M | $7.2M |
| Sep 2023 | — | $6.6M | $5.5M |
| Dec 2023 | — | $5.6M | $7.3M |
| Mar 2024 | — | $7.5M | $7.8M |
| Jun 2024 | — | $6.1M | $6.1M |
| Sep 2024 | — | $4.9M | $6.0M |
| Dec 2024 | — | $55.0M | $45.8M |
| Mar 2025 | — | $53.6M | $39.7M |
| Jun 2025 | — | $52.2M | $39.5M |
| Sep 2025 | — | $141.6M | $127.7M |
| Dec 2025 | — | $137.8M | $61.8M |
| Mar 2026 | — | $135.4M | $52.5M |
| Jun 2026 | — | $130.9M | $52.8M |